NewsVandana Singh
Generate Biomedicines
GENB · NASDAQ
$12.90+$0.34 (+2.71%)TodayMarket closed ·
Prev close $12.56
Latest news
- Press releaseGlobe Newswire
AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- News
Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration
- Press releaseGlobe Newswire
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
- Press releaseGlobe Newswire
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
- News
'Zealand Pharma Makes Deal With Generate Worth Up to $1.2 Billion' - Bloomberg
- Press releaseGlobe Newswire
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
- Press releaseGlobe Newswire
Generate Biomedicines Inc. to Participate in September Investor Conferences
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
- NewsAvi Kapoor
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- Press releasePRNewswire
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
- Press releasePRNewswire
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Press releasePRNewswire
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.